<SEC-DOCUMENT>0001144204-15-019138.txt : 20150330
<SEC-HEADER>0001144204-15-019138.hdr.sgml : 20150330
<ACCEPTANCE-DATETIME>20150330083706
ACCESSION NUMBER:		0001144204-15-019138
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150330
FILED AS OF DATE:		20150330
DATE AS OF CHANGE:		20150330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		15732562

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v405894_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: March 2015 (Report No.
4)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>BIO BLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">37 Dereh Menechem Begin St., 15<SUP>th</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Tel Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Form 20-F &nbsp;<FONT STYLE="font-family: Wingdings">x
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report of Foreign Private Issuer on
Form 6-K of the registrant consists of the press release issued by the registrant on March 30, 2015, announcing positive <I>in
vivo </I>preclinical proof-of-concept results of its Cabaletta Platform in Spinocerebellar Ataxia Type 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press
Release issued by Bio Blast Pharma Ltd. on March 30, 2015.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>Bio Blast Pharma Ltd.
        </U><BR>
        (Registrant)</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><U>By /s/ Colin Foster </U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Colin Foster</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 30, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v405894_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 53px; width: 248px"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BioBlast Pharma Announces Positive <I>in
vivo</I> Preclinical Proof-of-Concept Results of its Cabaletta Platform in Spinocerebellar Ataxia Type 3 (SCA3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEL AVIV, Israel, March 30, 2015</B> &ndash; BioBlast Pharma
Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company announced today positive <I>in vivo</I> proof-of-concept
results for Cabaletta for Spinocerebellar Ataxia Type 3 (also known as SCA3 or Machado Joseph disease). Results were presented
at the International Ataxia Research Conference held in Windsor UK, March 25-28, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cabaletta was tested in two different animal models of the disease:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>In a transfected mouse model, Cabaletta demonstrated efficacy in reducing the pathological cellular aggregates that are the
root cause of the extensive nerve damage characteristic of SCA3. In a series of experiments, Cabaletta reduced the protein aggregations
that are potentially toxic to neural cells, and reduced the biomarkers indicative of ubiquitin-imminent cell death. Immunohistochemistry
studies corroborated this effect by demonstrating prevention of Darpp-32 loss in treated animal cells, a sensitive biomarker of
neural damage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>In a transgenic mouse model, treatment with Cabaletta was effective in preventing and preserving neural functions in multiple
tests including the Rotarod and swimming tests.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Colin Foster, BioBlast&rsquo;s President and CEO commented:
&ldquo;Our <I>in vivo</I> proof-of-concept studies demonstrate Cabaletta&rsquo;s efficacy in reducing Ataxin3 aggregates, reducing
neural markers for neural damage and preventing typical phenotypic deterioration in animal models. As a whole, this is powerful
support for our ongoing SCA3 Phase 2 clinical trial program underway in Israel. We anticipate expanding the number of SCA3 clinical
study centers later this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;There are approximately two dozen diseases that Cabaletta
may address, given a common disease-causing mechanism related to intracellular and intranuclear protein aggregation. With Cabaletta,
we have previously reported on our ongoing oculopharyngeal muscular dystrophy (OPMD) Phase 2/3 multicenter clinical trial and our
preclinical work in spino bulbar muscular atrophy. Today, given the SCA3 proof-of-concept results, we share the fervent hopes of
the many SCA3 patients waiting anxiously for a treatment for this devastating disease.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About Cabaletta</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cabaletta is BioBlast&rsquo;s proprietary intravenous (IV) solution
of trehalose, a disaccharide, known for its capabilities in stabilizing intracellular and intranuclear proteins and enhancing autophagy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 53px; width: 248px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About Spinocerebellar Ataxia Type 3 (SCA3 or Machado Joseph
Disease)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SCA3, also known as Machado Joseph disease, is the most common
among the cerebellar ataxias, which are a group of genetic diseases that are characterized by gait and movement disorders memory
deficits, spasticity, difficulty with speech and swallowing, weakness in arms and other muscular anomalies. Symptoms can begin
in early adolescence and get worse over time. Eventually SCA3 leads to paralysis and severe disability. The disease typically appears
in the third or fourth decades of life and is associated with early death, on average within 15-20 years of diagnosis. There is
currently no approved treatment for the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About BioBlast</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast Pharma is a clinical-stage biotechnology company committed
to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse
portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BioBlast platforms are based on deep understanding of the
disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within
the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, we are using forward looking statements when we discuss making further progress toward providing
a therapy to help SCA3 patients, that our platforms potentially offer solutions for several diseases that share the same biological
pathology, including approximately two dozen diseases in the case of our Cabaletta product candidate, or when we discuss expanding
the number of SCA3 clinical studies and timing of such expansion. In addition, historic results of scientific research and clinical
and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions
or that historic results would not be interpreted differently in light of additional research and clinical and preclinical trials
results. Because such statements deal with future events and are based on BioBlast Pharma Ltd.'s current expectations, they are
subject to various risks and uncertainties and actual results, performance or achievements of Bio Blast Pharma could differ materially
from those described in or implied by the statements in this press release, including those discussed under the heading &quot;Risk
Factors&quot; in BioBlast Pharma's prospectus dated July 30, 2014 filed with the Securities and Exchange Commission (&quot;SEC&quot;)
and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation
to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information,
future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 53px; width: 248px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Investor Contact:<BR>
Michael Rice<BR>
Founding Partner<BR>
LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">646-597-6979</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``U`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BHKBXAM
M('GGD"1H,LQ[5P6H>,+S5+TV6EM]FAYW3XRVT=3[4FU%7>PTFW9'H)90<%@#
M]:4D`9/2O+6O9(I,I++*W=YFW,3Z^U37WBN^L?#<Z2R9DF!2%B?F]S]!7FX?
M-L/B*OLJ=V^]M#MJY?6I4_:3LEZZF?XU\9SWU_)I^GS%+.,E693_`*P]_P`*
MRO#6N76BWB20N3$3^\CSPPK!@L[JXDS'#(_?(%6X@\3[74JP[$8KTSA/?[:>
M.ZMHYXCE)%#*:EKGO!5P;CPU!N.?+8H/H*Z&@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#RWQUXC:ZU!]/A<BW@.
M&Q_$W_UJP-`ND_M!XF(#31,B'_:/05A7DEPMW*MP")@QW@^M5A(P8,"00<@B
MHJTU4@X/9JQ4)N$E)=#UK1?#PU2UEF:;RW5MJ@KN`/N*T/\`A`[-Y!/<3M<7
M&,;I5RH'H%[5A>!/%T#SM9W["*:0`+(3A7/OZ&O2NV:XL#@88:CR6UZOO\SJ
MQ6*E6J<U].B['"ZWHDFF6:R)>[U4X\LC!'TKFM207^GRO(!YUNA=9.^T=0:V
M_$6HQ7'BY[%9`PDM1LYXW]A5;3-%N=5#Q*I6%_DD8]E/7'O7E5:$Z.94_87Y
M9;ZMKS[GH0JQJX*?MK77E;T.J\#0-!X5MBPYE)D'T-<IXA\0:_>>-GT71+H1
M``)@G`#=R37I,44=K:I%&H$<284#T%>,:7I=YXK\7:K=VEX;1E9G\T>YQC]*
M^E/#.@\/>*-?M?%ZZ#J\D=QN;863G:?7/I6NLFI77Q"*P:U";.+[]HLG.!U&
MWU]ZY3P#(FG^+[^TNTCGN520_:LY*[>N#[U7\+W<D4WB/Q$.98(6*$_WF/'\
MJ`/5+_Q'H^F3^3>ZC!#+C.QFYJTFH6UQI[7EO.DL&PL'4Y%>4>%O#MAK&@ZG
MKNM2F5_F`9F^Z0,DG\Z@\*7LMIX+\2MYC")8U$63QN.1Q^E`$^F:QXR\0_;;
MBPOXTCMCN96;;UR<#UZ5T?@[QC>:IHNIOJ(4R64>[S5&-P(/7WXKB-.\-W[^
M"KK68=2,$>6WP;BH=1[UJZ7J4,'PIU)8X%BE+^2\@_CW=#3`V_AA=WU__:-W
M>7,TJ`JJ>8V0.I/]*ZVY\5Z#9SM#<:K;)(O52V<?E7EIU"XT/X;6D%N3'-J4
MSL7'!V#C%1>(=`T[0_"5@[?O-4NR)&?=T7'0#TY%(#V(:OIQT_[?]LA^R?\`
M/7=\M5K3Q/HE\9!;:E!(8T+O@]%'>O//$'AW49?`FB"RA:5+>(M<1IU)/.['
M?O5CPE-X=U#1]1VZ;]FNH[4I.%;[Z=R#VZ4`:]A\1(+[Q5)IY,$-BFX+.S?Z
MP@\?G797EQ]GL9IP?N(6!KR;X;^&;#5Y+J\O(F<0.ODX;'/7_"O2?$LODZ)(
MH_C(2L,55]E0G4[)FM"'/4C'NS$M[O7;NTEO(IQY<?4$XS^%6QKDMUX<N9'.
MV=,)N7C.>]4;"QUFXTQ8(2J6LOS9)QD&I-8LUTG1H;,-NDE?>Q]<"OEZ=3$P
MHNK>7+R._,]&WMR_>>U*%&510TOS:6[+>YHZ%J<$6G+]LO%$KL2`[9..U;Y=
M0F\L`N,YSQ7"ZII<&GZ7:-@_:9>6.?:K.JS3M'8:6K;<QJ7YZD]*[,/F-7#4
MW2JQNXJ-M=6Y;)WZG/5P<*TU.F])-_<NQTAUK30VTWD6<XZU8DO;:)D$DZ*7
MY7)ZUQ>L:?:VEY;6=L,R$#><YR2:GUZ)KG6[:RB.,(J#VS5O-<1!34X)N+BM
M&]WT^1*P-*3CRR=FF]>R.J&I6161A<Q[8SASGI37U:P0J&NX@6&5YZUSFN6,
M&E:6EM#DM,^6)/7`JCJNF16&GV6`?M$H)<YHKYIBJ7,G"-XI-ZOJ]@I8*A4L
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MW%A*<R!?O1-Z_3VKEIO$%I%&39P2/+C@RX`4^N!UKYVKA<TC5<:4[P?5O9?G
M]Q[4,1@94U*<+279;F=XEN776D*,5EAB1"1U##/^->H>!?$4>M:3Y+JB74'$
MBJ,!AV:O&;CSIYGFE8L[G+$]S70>`+J6U\6VJIG$N8V'L:]^G34(1BNBL>1.
M;G)R[NY[9<QO-;2QH^QW4J&]*\Z@^%]Y:F3[/KCQ"3A]BD;A[X->E459!R&D
M>`K31=/O([>=I+VXC,?VEUY4'T%/\/\`@B#2-'OM/N9OM"7G$A`QQC%=910!
MYFOPOO8O-M(=:=-/E;+)@\_49P:W[SP-;-X4&AV,Q@4R"1Y6&2Y'7-=;10!Y
MLGPNN3;K:RZY+]E!SY:J<?EG%;&H^`X)O#<.BV%P;>%)/,=F&XNV.IKL:*`.
M.U?P'#J7AJPTQ;C9+8KMCE(X/KFL5_A7+<00FXU>1YT^7+#*JO8"O2Z*`.-U
MOPEJUY=1S:?K4ELJPK$8URHP!['O3M#\!6VD:9?6[W+2SWL9227&-H]J["B@
M#B?"/@>Z\-:I)<-J!E@*E1$H(#9[D5TFL:6VJ0I$)?+"G)XSFM*BLZU*%:#I
MS5TRZ=25.2E'=$-K`+6UB@4Y"*%S6=JVBMJD\3F?8D8QMQ6O145<-3JT_937
MNZ:>A4*TX3YXO4Q]5T0ZE+"WG;$B&-N*9J_A\:A+'/%+Y<J`*?<#I6W1653+
M\/4YN:/Q6O\`+8N&*JPY>5[;?,YR+PN8[R*Y:Z9W4AFW#J:MKHG_`!.SJ+S9
MYR$QTK8HJ89;AH:1CUON]UU'+&5I;OI;Y&3JVC'5)H6,VQ8^V.M-U+1#J%U!
M(9MJ1`#;CK6Q15SP-"HY.4?BLW\MB8XFK&UGM>WS,>_T0WVH0W#382,`;,>E
M1:IX>-[>K=P3>5)QG\.];M%34R_#U%)2C\3N]7NAPQ=6%K/96.?M?#(MM1BN
MOM)<H=QW#DFBN@HK7#X6EATXTE9/4BK6G5:<W>P4445T&0UT61&1U#*PP01D
M&N,UKP%ICK+=VS-;D#<4494_3THHH`\\N+%([KR0V1G&<5Z/X.\)V6G*FI[V
MEN'7"[A@(.]%%`'8T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
5110`4444`%%%%`!1110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
